ASAS20/40 treatment effects have declined over time in axSpA trials, consistent with a fading of reported effectiveness, whereas ASDAS-based endpoints remain stable, indicating greater robustness to placebo effects and temporal trends.

25 days ago

Retrospective data • Journal

IL17A (Interleukin 17A) • CRP (C-reactive protein)

Cosentyx (secukinumab) • Simponi (golimumab)

Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek-Turkish collaborative study. (PubMed, Eur J Gastroenterol Hepatol)

One quarter of IBD patients requiring intensified anti-TNFa therapie were successfully deescalated to standard dosing, after a median of 16.0 (IQR: 8.0-36.0) months.

1 month ago

Journal • Real-world evidence

TNFA (Tumor Necrosis Factor-Alpha)

Simponi (golimumab)

2ms

Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov)

P2, N=35, Not yet recruiting, Sun Yat-sen University

2 months ago

New P2 trial

PD-L1 (Programmed death ligand 1)

Lucentis (ranibizumab) • Simponi (golimumab)

2ms

EFFECT-1LAT: Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population (clinicaltrials.gov)

P=N/A, N=4000, Not yet recruiting, Pfizer | Trial completion date: Oct 2025 --> Mar 2026 | Initiation date: Sep 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Mar 2026

2 months ago

Trial completion date • Trial initiation date • Trial primary completion date

tofacitinib • Entyvio (vedolizumab) • Simponi (golimumab)

3ms

EVOLUTION: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (clinicaltrials.gov)

P3, N=63, Recruiting, University of Pennsylvania | N=150 --> 63 | Trial completion date: May 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Oct 2026

3 months ago

Enrollment change • Trial completion date • Trial primary completion date

Simponi (golimumab)

4ms

Biological therapy in a patient with coexistence of multiple sclerosis and ankylosing spondylitis: a case based review. (PubMed, Rheumatol Int)

Tumor necrosis alpha (TNF-alpha) inhibitors are a group of biologics approved for treatment of AS (e.g. adalimumab, certolizumab pegol, golimumab, infliximab, etanercept), and they are usually first choice of treatment when starting biological therapy. Another group of biologic agents approved for the treatment of AS are interleukin-17 (IL-17) inhibitors, such as secukinumab and ixekizumab...The selected therapy proved to be effective, leading to a notable reduction in overall pain and morning stiffness. Clinical improvement was measured by a decrease in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), which dropped from 5.3 prior to treatment to 2.95 after six months of therapy.

4 months ago

Review • Journal

IL17A (Interleukin 17A)

Cosentyx (secukinumab) • Simponi (golimumab)

4ms

Developing models for the diagnosing of ulcerative colitis and prognosis of anti-TNF-α non-response based on neutrophil extracellular trap-associated genes. (PubMed, Front Immunol)

This study aims to identify key NET-associated molecular signatures in UC, develop diagnostic models based on NET-related biomarkers, and construct predictive models for response to anti-TNF-α therapies (infliximab and golimumab). A distinct NET-associated cluster was identified among patients with UC, exhibiting non-responsiveness to anti-TNF-α treatment. Diagnostic and prognostic models based on NET-associated genes hold promise for guiding clinical treatment strategies.

4 months ago

Journal

IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL2 (Interleukin 2) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • IL1RN (Interleukin 1 receptor antagonist)

Simponi (golimumab)

4ms

EFFECT-1LAT: Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population (clinicaltrials.gov)

P=N/A, N=4000, Not yet recruiting, Pfizer

4 months ago

New trial

tofacitinib • Entyvio (vedolizumab) • Simponi (golimumab)

4ms

Analysis of the potential for immunosuppression of infants with in-utero and breast milk exposure to antitumor necrosis factor alpha agents: are all agents equally safe? (PubMed, Int J Womens Dermatol)

Studies reporting on infant infection rates, vaccination outcomes, and adverse events following in-utero or breastfeeding exposure to TNFi agents, including certolizumab pegol, adalimumab, infliximab, etanercept, and golimumab. The data indicate that TNFi does not increase the risk of severe infections or vaccine complications in infants, with the exception of the Bacille Calmette-Guerin vaccine, for which a more cautious approach is recommended. These findings reinforce the use of TNFi in women with inflammatory conditions who are pregnant or breastfeeding, providing benefits to both maternal and fetal health.

4 months ago

Review • Journal

TNFA (Tumor Necrosis Factor-Alpha)

Simponi (golimumab)

5ms

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov)

P2, N=80, Not yet recruiting, NYU Langone Health

5 months ago

New P2 trial

Rituxan (rituximab) • hydroxychloroquine • Actemra IV (tocilizumab) • cyclosporine • tofacitinib • Cosentyx (secukinumab) • Ilaris (canakinumab) • Kineret (anakinra) • Simponi (golimumab) • leflunomide

5ms

PURSUIT 2: A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov)

P3, N=84, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2027 --> Feb 2027

5 months ago

Trial completion date

Simponi (golimumab)